The APROVE (Anti-coagulation/Platelet Treatment in Pancreatic Resections Involving Vascular Reconstruction) Study: Results from a Worldwide Survey

Publication date

2025

Authors

Marchetti, Alessio
Garnier, Jonathan
Habib, Joseph R
Rompen, Ingmar F.
Andel, Paul
Salinas, Camila Hidalgo
Ratner, Molly
De Pastena, Matteo
Salvia, Roberto
Hewitt, D. Brock

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

Background: Antithrombotic therapy (AT) aims to strike a balance between preventing thromboembolic and hemorrhagic complications. However, evidence for AT management after pancreatectomy with vascular reconstruction is lacking. We aimed to provide an overview of the current use of AT for pancreatic surgery with vascular reconstructions. Patients and Methods: A web-based survey was distributed to 123 surgeons from high-volume pancreas centers (>50 pancreatic resections/year). AT management after different types of vascular reconstruction were investigated. An “aggressive” protocol was defined as the use of any AT protocol other than prophylactic heparin, aspirin, or their combination. Results: The survey was completed by 80 surgeons (59% Europe, 30% USA, 11% Asia). In Europe/Asia, prophylactic heparin was the most commonly reported protocol after partial venous resection/end-to-end anastomosis/human graft (71%/65%/50%, respectively), and an “aggressive” protocol (86%) was the most frequently used after prosthetic graft reconstruction. Conversely, in the USA, prophylactic heparin + aspirin was the most commonly reported protocol after all types of venous reconstruction. Following arterial reconstruction, heparin + aspirin was the most commonly reported protocol, regardless of region. An “aggressive” protocol was more frequently used in Europe/Asia (odds ratio (OR) 1.28; p < 0.001) and following vein reconstruction with either human graft (OR 1.2; p = 0.007) or prosthetic graft (OR 1.56, p <0.001), while ultrasound (OR 1.65; p < 0.001) and arterial reconstruction (OR 1.64; p < 0.001) were significantly associated with antiplatelet use. Conclusions: In an international cohort of high-volume pancreas surgeons, significant variation in the use of AT following pancreatectomy with vascular reconstruction was observed. This variation was driven by geographical differences and the type of vascular reconstructions performed. Mini Abstract: In an international cohort of high-volume pancreas surgeons, this Worldwide Snapshot Survey analyzed the current use of antithrombotic therapy for pancreatic surgery with vascular reconstruction. A significant heterogeneity in antithrombotic practice was found and it was mainly driven by geographical differences and the type of vascular reconstructions performed.

Keywords

Anticoagulants, Antiplatelets, Antithrombotic therapy, Pancreatic surgery, Vascular reconstruction, Taverne, Surgery, Oncology

Citation

Marchetti, A, Garnier, J, Habib, J R, Rompen, I F, Andel, P C M, Salinas, C H, Ratner, M, De Pastena, M, Salvia, R, Hewitt, D B, Morgan, K, Kluger, M D, Garg, K, Javed, A A, Wolfgang, C L & Sacks, G D 2025, 'The APROVE (Anti-coagulation/Platelet Treatment in Pancreatic Resections Involving Vascular Reconstruction) Study : Results from a Worldwide Survey', Annals of surgical oncology, vol. 32, no. 10, pp. 7400–7409. https://doi.org/10.1245/s10434-025-17686-y